Retinal disease patients with indicated treatment with intravitreal anti-VEGF injections Anti-vascular endothelial growth factor (VEGF) Fixed combination anti-glaucoma medication Intraocular pressure spike Intravitreal injections Prophylactic anti-glaucoma medication
Conditions
Interventions
The IOP-lowering medications were given 1 h before intravitreal anti-VEGF injections in the one-drop regimen, and 1 h and 5 min before intravitreal anti-VEGF injections for the two-drop regimen.,The I
dorzolamide-timolol,brimonidine /timolol ,brinzolamide/brimonidine,controll
Sponsors
Mettapracharak (Wat Rai Khing) hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: participant who had indicated treatment with intravitreal anti-VEGF injections (bevacizumab, aflibercept and ranibizumab)
Exclusion criteria
Exclusion criteria: 1.participants who required an intracameral drainage 2.participants who allergy to the drugs and their components used in this study as well as fluoroquinolone, sulfamycin, and anti-VEGF 3. participants who underlying diseases of asthma, chronic obstructive pulmonary disease (COPD), and heart disease, corneal diseases 4.participants who treatment of intravitreal steroid injections within the past three months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| intraocular pressure 30 mins and 1 hour I care tonometry | — |
Secondary
| Measure | Time frame |
|---|---|
| n/a n/a n/a | — |
Countries
Thailand
Contacts
Public Contactkulawan rojananuangnit
Mettapracharak (Wat Rai Khing) hospital
Outcome results
None listed